Both ALBI score (<i>OR = 0.113, 95% CI: 0.014-0.904</i>) and age (<i>OR = 0.935, 95% CI: 0.875-1.000</i>) were independent predictors of trastuzumab resistance in HER2-positive BC patients. Here, ERBB2 is linked to breast cancer.